HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells

Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of low, minimally cytotoxic concentrations of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells. Cell li...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biotherapy & radiopharmaceuticals Vol. 24; no. 6; p. 689
Main Authors: Chen, Xufeng, Wong, Patty, Radany, Eric, Wong, Jeffrey Y C
Format: Journal Article
Language:English
Published: United States 01-12-2009
Subjects:
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of low, minimally cytotoxic concentrations of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells. Cell lines LS174T and an isogenic pair of HCT116, which differed only for the presence of wild-type p53, were exposed to ionizing radiation (IR) alone, VPA alone, or the combination. Clonogenic survival, gamma-H2AX induction, apoptosis, changes in mitochondrial membrane potential, and mitochondrial levels of p53 and Bcl-2 family proteins were assessed. In vivo studies monitored tumor growth suppression after therapy in mice bearing HCT116/p53(+/+) and HCT116/p53(-/-) tumor xenografts. VPA led to radiosensitization, which was dependent on p53 status. A decrease in clonogenic survival, an increase in apoptosis, and an increase in levels of gamma-H2AX were observed after VPA+IR, compared to IR alone, in wild-type p53 cells (LS174T and HCT116/p53(+/+)), as opposed to p53 null cells (HCT116/p53(-/-)). Exposure to VPA resulted in enhancement of IR-induced mitochondrial localizations of Bax and Bcl-xL, mitochondrial membrane potential, and cytochrome c release only in wild-type p53 cell lines. VPA also enhanced tumor growth suppression after IR only in wild-type p53 xenografts. These data suggest that VPA may have an important role in enhancing radiotherapy response in colorectal cancer, particularly in tumors with the wild-type p53 genotype.
AbstractList Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of low, minimally cytotoxic concentrations of the HDAC inhibitor, valproic acid (VPA), on radiation response of colorectal cancer cells. Cell lines LS174T and an isogenic pair of HCT116, which differed only for the presence of wild-type p53, were exposed to ionizing radiation (IR) alone, VPA alone, or the combination. Clonogenic survival, gamma-H2AX induction, apoptosis, changes in mitochondrial membrane potential, and mitochondrial levels of p53 and Bcl-2 family proteins were assessed. In vivo studies monitored tumor growth suppression after therapy in mice bearing HCT116/p53(+/+) and HCT116/p53(-/-) tumor xenografts. VPA led to radiosensitization, which was dependent on p53 status. A decrease in clonogenic survival, an increase in apoptosis, and an increase in levels of gamma-H2AX were observed after VPA+IR, compared to IR alone, in wild-type p53 cells (LS174T and HCT116/p53(+/+)), as opposed to p53 null cells (HCT116/p53(-/-)). Exposure to VPA resulted in enhancement of IR-induced mitochondrial localizations of Bax and Bcl-xL, mitochondrial membrane potential, and cytochrome c release only in wild-type p53 cell lines. VPA also enhanced tumor growth suppression after IR only in wild-type p53 xenografts. These data suggest that VPA may have an important role in enhancing radiotherapy response in colorectal cancer, particularly in tumors with the wild-type p53 genotype.
Author Chen, Xufeng
Wong, Jeffrey Y C
Radany, Eric
Wong, Patty
Author_xml – sequence: 1
  givenname: Xufeng
  surname: Chen
  fullname: Chen, Xufeng
  organization: Department of Radiation Oncology, City of Hope Cancer Center, Duarte, California 91010, USA
– sequence: 2
  givenname: Patty
  surname: Wong
  fullname: Wong, Patty
– sequence: 3
  givenname: Eric
  surname: Radany
  fullname: Radany, Eric
– sequence: 4
  givenname: Jeffrey Y C
  surname: Wong
  fullname: Wong, Jeffrey Y C
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20025549$$D View this record in MEDLINE/PubMed
BookMark eNo1j0tLAzEYRYMo9qFLt5If0Bm_ySSTZFnGaoWCG11KyRMj02RIpoL-egvq6l44lwN3gc5jig6hmwbqBoS8MzrXBEDW0BF5huYNY7wSgpEZWpTyAQAddPwSzU4jwhiVc_S2vV_3OMT3oMOU8gp_qmHMKRisTLCrE7FH4woeWVtZN7poXZxwVjak4mIJU_hWU0gRJ49NGk7FqGhcxsYNQ7lCF14NxV3_5RK9Pmxe-m21e3586te7ylDRTpVvlBKCK-c1NUKD5bKVgjoLVoAgsjOeatp0ynHfcqEF9bazXADjsjFUkSW6_fWOR31wdj_mcFD5a___k_wAJJNVMw
CitedBy_id crossref_primary_10_1016_j_ajme_2017_04_002
crossref_primary_10_3892_ol_2013_1245
crossref_primary_10_3892_ol_2017_5792
crossref_primary_10_1186_s13048_016_0267_2
crossref_primary_10_3389_fonc_2021_722754
crossref_primary_10_1111_j_1582_4934_2011_01296_x
crossref_primary_10_1517_13543784_2012_694425
crossref_primary_10_1007_s00438_010_0550_7
crossref_primary_10_1016_j_freeradbiomed_2014_05_019
crossref_primary_10_1007_s10637_018_0696_4
crossref_primary_10_1089_omi_2010_0026
crossref_primary_10_18632_oncotarget_10790
crossref_primary_10_3892_or_2015_4089
crossref_primary_10_1259_bjr_20140649
crossref_primary_10_1016_j_canlet_2014_09_049
crossref_primary_10_1186_1748_717X_9_89
crossref_primary_10_1007_s11060_011_0725_z
crossref_primary_10_3109_02688697_2011_638996
crossref_primary_10_1007_s00432_011_1093_y
crossref_primary_10_1155_2017_6326053
crossref_primary_10_18632_oncotarget_5253
crossref_primary_10_4103_abr_abr_91_19
crossref_primary_10_1002_cbin_11591
crossref_primary_10_17795_jjnpp_22818
crossref_primary_10_2217_fon_2020_0385
crossref_primary_10_1371_journal_pone_0016795
crossref_primary_10_1016_j_procbio_2014_07_022
crossref_primary_10_3892_or_2015_3879
crossref_primary_10_1155_2013_374593
crossref_primary_10_1038_bjc_2013_21
crossref_primary_10_1186_s13148_021_01025_5
crossref_primary_10_1039_C5TX00476D
crossref_primary_10_1017_erm_2024_15
crossref_primary_10_1021_acs_jmedchem_0c00491
crossref_primary_10_1517_13543784_2013_853037
crossref_primary_10_1038_s41598_021_92466_8
crossref_primary_10_1093_jrr_rrt227
crossref_primary_10_3892_ol_2013_1666
crossref_primary_10_1038_bjc_2016_278
crossref_primary_10_1109_TCBB_2020_3019781
crossref_primary_10_1186_s13046_017_0647_5
crossref_primary_10_1007_s11060_013_1129_z
crossref_primary_10_3389_fonc_2021_646256
crossref_primary_10_1038_s41598_017_15165_3
crossref_primary_10_3390_radiation2010011
crossref_primary_10_1007_s11033_014_3246_y
crossref_primary_10_1016_j_radonc_2015_10_009
crossref_primary_10_1016_j_tranon_2016_12_011
crossref_primary_10_2217_fon_10_53
crossref_primary_10_1186_s12935_016_0306_5
crossref_primary_10_18632_oncotarget_3692
crossref_primary_10_1007_s11060_012_0978_1
crossref_primary_10_1155_2011_514261
crossref_primary_10_1002_adtp_202300421
crossref_primary_10_1007_s10495_014_1042_8
crossref_primary_10_1186_1752_0509_9_S5_S4
crossref_primary_10_1038_s41598_019_40054_2
crossref_primary_10_1007_s11523_015_0370_0
crossref_primary_10_1080_07391102_2017_1302820
crossref_primary_10_1089_omi_2010_0053
crossref_primary_10_3390_cancers13194905
crossref_primary_10_1177_2050640618792819
crossref_primary_10_4143_crt_2014_026
crossref_primary_10_1186_s12967_021_03171_z
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1089/cbr.2009.0629
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1557-8852
ExternalDocumentID 20025549
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: CA 33572
GroupedDBID ---
.GJ
0R~
1-M
29B
34G
39C
3V.
4.4
53G
5GY
5RE
6PF
7X7
88A
88E
88I
8C1
8FE
8FH
8FI
8FJ
8WZ
A6W
AAWTL
ABBKN
ABJNI
ABUWG
ACGFS
ACGOD
ACPRK
ADBBV
AENEX
AFKRA
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BBNVY
BENPR
BHPHI
BNQNF
BPHCQ
BVXVI
CAG
CCPQU
CGR
COF
CS3
CUY
CVF
DU5
DWQXO
EBS
ECM
EIF
EJD
F5P
FYUFA
GNUQQ
HCIFZ
HMCUK
IAO
IHR
IM4
INH
INR
ITC
L7B
LK8
M0L
M1P
M2P
M7P
NPM
O9-
P2P
PQQKQ
PROAC
PSQYO
RIG
RML
RMSOB
UDS
UE5
UKHRP
ZGI
ID FETCH-LOGICAL-c483t-f1aa887aefb4c8b0d793984ed0d808296cf4b416ae7f378b84fd6d7805791c4a2
IngestDate Sat Sep 28 07:46:34 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c483t-f1aa887aefb4c8b0d793984ed0d808296cf4b416ae7f378b84fd6d7805791c4a2
OpenAccessLink https://europepmc.org/articles/pmc2920759?pdf=render
PMID 20025549
ParticipantIDs pubmed_primary_20025549
PublicationCentury 2000
PublicationDate 2009-Dec
PublicationDateYYYYMMDD 2009-12-01
PublicationDate_xml – month: 12
  year: 2009
  text: 2009-Dec
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer biotherapy & radiopharmaceuticals
PublicationTitleAlternate Cancer Biother Radiopharm
PublicationYear 2009
References 17464244 - Cancer J. 2007 Jan-Feb;13(1):30-9
16830229 - Apoptosis. 2006 Aug;11(8):1349-57
9488723 - J Biol Chem. 1998 Mar 6;273(10):5858-68
15746940 - Cell Death Differ. 2005 May;12(5):482-91
14729640 - Cancer Res. 2004 Jan 1;64(1):316-21
12667443 - Mol Cell. 2003 Mar;11(3):577-90
15179185 - Melanoma Res. 2004 Jun;14(3):173-81
7624142 - Oncogene. 1995 Jul 20;11(2):253-61
10101800 - Semin Cancer Biol. 1998;8(5):345-57
9581811 - Cancer Res. 1998 May 1;58(9):1779-84
15077143 - Oncogene. 2004 Apr 12;23(16):2797-808
15050820 - J Mol Biol. 2004 Apr 16;338(1):17-31
15496622 - N Engl J Med. 2004 Oct 21;351(17):1731-40
6739728 - Radiat Res. 1984 Jul;99(1):73-84
11861406 - Cancer Res. 2002 Feb 15;62(4):1213-21
7930835 - Int J Radiat Biol. 1994 Oct;66(4):329-41
11790986 - Curr Opin Oncol. 2002 Jan;14(1):86-91
15867370 - Cancer Res. 2005 May 1;65(9):3745-50
12667439 - Mol Cell. 2003 Mar;11(3):552-4
9135890 - Clin Oncol (R Coll Radiol). 1997;9(2):70-8
15549093 - Nature. 2004 Nov 18;432(7015):316-23
7983426 - Int J Radiat Biol. 1994 Nov;66(5):427-32
14528271 - Oncogene. 2003 Sep 29;22(42):6479-83
16079181 - Mol Biol Cell. 2005 Oct;16(10):4623-35
15383798 - Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8
17380162 - Nat Rev Mol Cell Biol. 2007 Apr;8(4):284-95
12878854 - Cancer Biol Ther. 2003 May-Jun;2(3):233-5
15078986 - Mol Cancer Ther. 2004 Apr;3(4):425-35
1511188 - Crit Rev Eukaryot Gene Expr. 1992;2(3):251-63
11677656 - Semin Radiat Oncol. 2001 Oct;11(4):316-27
1679088 - Int J Radiat Biol. 1991 Sep;60(3):483-96
15069698 - Int J Cancer. 2004 Jun 10;110(2):301-8
12175305 - Radiat Res. 2002 Sep;158(3):251-91
14612513 - Cancer Res. 2003 Nov 1;63(21):7190-6
15850925 - Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):223-9
7973635 - Science. 1994 Nov 4;266(5186):807-10
15234026 - Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42
8917731 - Experientia. 1996 Oct 31;52(10-11):1001-7
14963330 - Science. 2004 Feb 13;303(5660):1010-4
11062378 - Mol Urol. 2000 Fall;4(3):225-9;discussion 231
17121856 - J Biol Chem. 2007 Feb 16;282(7):4765-71
4674589 - Radiat Res. 1972 Nov;52(2):373-94
12892709 - Cancer Cell. 2003 Jul;4(1):13-8
12907619 - Cancer Res. 2003 Aug 1;63(15):4460-71
12972501 - J Cell Sci. 2003 Oct 15;116(Pt 20):4077-85
18765532 - Clin Cancer Res. 2008 Sep 1;14(17):5410-5
1933891 - Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11
9822382 - Science. 1998 Nov 20;282(5393):1497-501
15077116 - Nat Cell Biol. 2004 May;6(5):443-50
11547717 - N Engl J Med. 2001 Aug 30;345(9):638-46
References_xml
SSID ssj0006067
Score 2.2235193
Snippet Agents that inhibit histone deacetylases (HDAC inhibitors) have been shown to enhance radiation response. The aim of this study was to evaluate the effects of...
SourceID pubmed
SourceType Index Database
StartPage 689
SubjectTerms Animals
bcl-2-Associated X Protein - drug effects
bcl-2-Associated X Protein - metabolism
Cell Cycle - radiation effects
Cell Division - drug effects
Cell Division - radiation effects
Cell Line, Tumor
Colorectal Neoplasms - pathology
Colorectal Neoplasms - radiotherapy
Cytochromes c - metabolism
Cytochromes c - radiation effects
Flow Cytometry
Genotype
Histone Deacetylase Inhibitors - pharmacology
Humans
Membrane Potentials - radiation effects
Mice
Mitochondria - metabolism
Mitochondria - radiation effects
Mitochondrial Membranes - physiology
Mitochondrial Membranes - radiation effects
Radiation-Sensitizing Agents - pharmacology
T-Lymphocytes - immunology
T-Lymphocytes - radiation effects
Tumor Suppressor Protein p53 - deficiency
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
Valproic Acid - pharmacology
Title HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells
URI https://www.ncbi.nlm.nih.gov/pubmed/20025549
Volume 24
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NS8MwFA-bgngRv78lB_GyFbs1a9Oj1MkuytAJehDJJxZ0G1t38L_3pUm7biLowUspSRtCfj9e3nu8D4TOWzSiXMbCE4AwGCg68KhSzJM6lkx3QsYCk43ce4junuh1l3RrtaJD1XzsX5GGMcDaZM7-Ae1yURiAd8AcnoA6PH-Fe-_6Kmmkw7eUp5k1xWF1EJOmLqtIczzBDJ-ZQKwxnFvRBDdrTJhMR1MTz5653Ewbcv4OL8JwY9IwXv5pVZ1N7DhPXR6XDb_JVxq_VZ3lpeaeuGyQp5lW7tKsBAb3WZaVPv57JkFSFcJ6-VOXgtZ4dn7ewnMRV6JAlJO2HbgiaWdBHNuUake7qmwNba-hbzLfp6ZkquATV300bC98B_CMP3Kw27kBRX4xu1SCu5iqozooVEbnTm7L6x4swMgVb4WdXC7sw5Sadv8umS25-jLYRBvO7sBXljBbqKaG22jt1kVWbKOLvsXrs4kH85S8aRNf4P68uvnnDnoxBMMlwZq4oBc29GpiRy68QC78nVx4pHFOLmzJhXNy7aLHm-4g6XmuR4cnCA0yT7cYg3uKKc2JoNyXIO9jSpT0JTVp26HQhIPSz1SkAxALlGgZStNII4pbgrD2HloZjobqAOFASlD-eSA7vEV0wGNf-pwr0N852MhUHKJ9e4KvY1uI5bU426MfZ47R-px5J2hVA-HVKapP5ewsh_ELh6V0zg
link.rule.ids 782
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HDAC+inhibitor%2C+valproic+acid%2C+induces+p53-dependent+radiosensitization+of+colon+cancer+cells&rft.jtitle=Cancer+biotherapy+%26+radiopharmaceuticals&rft.au=Chen%2C+Xufeng&rft.au=Wong%2C+Patty&rft.au=Radany%2C+Eric&rft.au=Wong%2C+Jeffrey+Y+C&rft.date=2009-12-01&rft.eissn=1557-8852&rft.volume=24&rft.issue=6&rft.spage=689&rft_id=info:doi/10.1089%2Fcbr.2009.0629&rft_id=info%3Apmid%2F20025549&rft_id=info%3Apmid%2F20025549&rft.externalDocID=20025549